OVID Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
-100.0%
733.0K
0
-100.0%
718.0K
+443.9%
132.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
0
-100.0%
733.0K
0
-100.0%
718.0K
+443.9%
132.0K
Operating Expenses
22.4M
+36.1%
16.4M
-7.9%
17.8M
+37.2%
13.0M
+2.8%
12.7M
R&D
15.7M
+57.6%
10.0M
-10.9%
11.2M
+69.7%
6.6M
+12.2%
5.9M
SG&A
6.7M
+3.0%
6.5M
-2.9%
6.7M
+3.8%
6.4M
-5.4%
6.8M
Operating Income
-22364000
-42.5%
-15698000
+12.0%
-17846000
-45.2%
-12293000
+1.8%
-12523000
EBITDA
-22349000
-42.5%
-15682000
+12.0%
-17811000
-45.1%
-12276000
+1.8%
-12507000
Net Income
-20780000
-38.5%
-15009000
+11.6%
-16988000
-275.8%
9.7M
+179.5%
-12158000
EPS (Basic)
$-0.10
-25.0%
$-0.08
+33.3%
$-0.12
-200.0%
$0.12
+170.6%
$-0.17
EPS (Diluted)
$-0.10
-25.0%
$-0.08
+33.3%
$-0.12
-200.0%
$0.12
+170.6%
$-0.17
Shares (Diluted)
203.0M
+2.8%
197.5M
+45.0%
136.2M
+66.7%
81.7M
+14.8%
71.1M
Ovid Therapeutics (OVID) — Financials